Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019–2026
The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026.
Psoriatic arthritis is an autoimmune disease caused by an attack of body’s immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.
Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.
The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets. • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities. • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type • NSAIDs • DMARDs • Biologics • Others
By Type • Prescription • OTC
By Route of Administration • Topical • Oral • Injectable
By Region • North America o U.S. o Canada o Mexico • Europe o Germany o France o UK o Italy o Spain o Rest of Europe • Asia-Pacific o Japan o China o Australia o India o South Korea o Rest of Asia-Pacific • LAMEA o Brazil o Saudi Arabia o South Africa o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT • AbbVie Inc. • Amgen Inc. • Bristol-Myers Squibb Company • Celgene Corporation • Eli Lilly And Company • Johnson & Johnson • Merck & Co Inc. • Novartis AG • Pfizer Inc. • UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.) • F. Hoffmann-La Roche AG • Valeant Pharmaceuticals International, Inc. • Abbott Laboratories
Our reports have been used by over 10K customers, including:
Myasthenia Gravis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2020" provides an overview of Myasthenia Gravis Clinical trials scenario.This report provides top line data relating to the clinical trials on Myasthenia...
Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020 Summary According to the recently published report ’Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020’; Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)...
Vitiligo - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape. Vitiligo is a condition in which skin loses melanin, the pigment that determines...
Adenosine Receptor A3 - Pipeline Review, H2 2020 Summary Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Pipeline...